New combo therapy shows promise in leukemia trial
NCT ID NCT07211958
First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 24 times
Summary
This study tests whether adding the drug revumenib to standard chemotherapy helps people with a certain genetic type of acute myeloid leukemia (AML) live longer without the cancer coming back. About 468 adults with newly diagnosed AML and an NPM1 mutation will receive either revumenib plus chemo or a placebo plus chemo. The goal is to see if the combination improves remission rates and survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Trial Site
RECRUITINGBatumi, Adjara, 6000, Georgia
-
Clinical Trial Site
RECRUITINGTbilisi, 0112, Georgia
-
Clinical Trial Site
RECRUITINGTbilisi, 0186, Georgia
-
Clinical Trial Site
RECRUITINGDüsseldorf, North Rhine-Westphalia, 40479, Germany
-
Clinical Trial Site
RECRUITINGJerusalem, 91031, Israel
-
Clinical Trial Site
RECRUITINGCandiolo, 10060, Italy
-
Clinical Trial Site
RECRUITINGPalermo, 90146, Italy
-
Clinical Trial Site
RECRUITINGGoyang-si, 10408, South Korea
-
Clinical Trial Site
RECRUITINGSeoul, 03080, South Korea
-
Clinical Trial Site
RECRUITINGSeoul, 06591, South Korea
-
Clinical Trial Site
RECRUITINGLondon, W12 0HS, United Kingdom
-
Clinical Trial Site
RECRUITINGSutton, SM2 5PT, United Kingdom
-
Clinical Trial Site 1
RECRUITINGTbilisi, 0159, Georgia
-
Clinical Trial Site 2
RECRUITINGTbilisi, 0159, Georgia
Conditions
Explore the condition pages connected to this study.